The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.25
Bid: 35.00
Ask: 35.50
Change: 0.50 (1.44%)
Spread: 0.50 (1.429%)
Open: 34.75
High: 35.30
Low: 35.25
Prev. Close: 34.75
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

21 Feb 2023 10:29

RNS Number : 5839Q
Creo Medical Group PLC
21 February 2023
 

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Creo Medical Group PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify):

3. Details of person subject to the notification obligation

Name

The Capital Group Companies, Inc.

City and country of registered office (if applicable)

Los Angeles, USA

4. Full name of shareholder(s)  (if different from 3.)

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached:

17/02/2023

6. Date on which issuer notified (DD/MM/YYYY):

20/02/2023

7. Total positions of person(s) subject to the notification obligation:

% of voting rights attached to shares

(total of 8.A)

% of voting rights through financial instruments

(total of 8.B.1 + 8.B.2)

Total of both in %

(8.A + 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

4.84%

0.00%

4.84%

182,342,363

Position of previous notification (if applicable)

7.13%

0.03%

7.16%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Voting rights attached to shares

Class/type of shares ISIN code (if possible)

Number of voting rights

% of voting rights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BZ1BLL44 Common Stock

8,816,807

4.84%

SUBTOTAL 8.A

8,816,807

4.84%

B 1: Financial Instruments DTR5.3.1R (1) (a)

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

N/A

SUBTOTAL 8.B.1

B 2: Financial Instruments with similar economic effect DTR5.3.1R (1) (b)

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Physical or cash settlement

Number of voting rights

% of voting rights

N/A

SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Capital Research and Management Company

Total

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information:

 

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of six investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl, Capital International K.K., Capital Group Private Client Services Inc, and Capital Group Investment Management Private Limited. CGII management companies and CB&T primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based investment management company that is a registered investment adviser and an affiliated federally chartered bank.

Neither CGC nor any of its affiliates own shares of the Issuer for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

 

 

Place of completion

Los Angeles

Date of completion

20/02/2023

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAEAFAASDEFA
Date   Source Headline
23rd Mar 20207:00 amRNSFDA Clearance for HS1 Haemostasis Device
20th Mar 20207:00 amRNSTrading update – COVID-19 impact
4th Mar 20205:00 pmRNSExercise of Options
24th Feb 20203:49 pmRNSHolding(s) in Company
19th Feb 20207:00 amRNSLTIP Awards and Issue of Equity
11th Feb 20207:00 amRNSVideo abstracts re. Speedboat procedures in India
7th Feb 202011:50 amRNSExercise of Options
6th Feb 20207:00 amRNSGrowth & Innovation Forum 2020
3rd Feb 20207:00 amRNSAppointment of NED
30th Jan 20207:00 amRNSTrading update
30th Dec 20193:17 pmRNSHolding(s) in Company
27th Dec 20195:00 pmRNSHolding(s) in Company
24th Dec 20198:01 amRNSDirector/PDMR Shareholding
23rd Dec 201911:15 amRNSResult of General Meeting and Total Voting Rights
23rd Dec 20197:00 amRNSResult of Open Offer
4th Dec 20197:00 amRNSRe. Placing, Open Offer, and Posting of Circular
2nd Dec 20197:00 amRNSFundraising and Launch of Accelerated Book Build
20th Nov 20197:00 amRNSFirst in-human cases in India
22nd Oct 20197:00 amRNSCommercial Launch of Speedboat at UEG Week
17th Oct 20197:00 amRNSUK Endoscopy Training Course
30th Sep 20197:00 amRNSHalf-year Report
26th Sep 20197:00 amRNSFramework Distribution Agreement for India
23rd Sep 20192:16 pmRNSNotice of Results
10th Sep 20197:00 amRNSUS Clinical Education Programme enters Phase II
7th Aug 20191:57 pmRNSDirector/PDMR Shareholding
5th Jul 20197:00 amRNSInstitute of Physics Award
25th Jun 20197:00 amRNSFirst commercial orders for Speedboat
6th Jun 20191:23 pmRNSResult of AGM
13th May 201910:50 amRNSAnnual Reports & Accounts & Notice of AGM
10th May 20197:00 amRNSMello 2019
24th Apr 20197:00 amRNSNew video abstract featuring Speedboat published
5th Apr 20197:00 amRNSFinal Results
28th Mar 20197:00 amRNSUpdate on US Clinical Education Programme
21st Mar 20192:34 pmRNSExercise of Options
21st Mar 20197:00 amRNSNotice of results and investor briefing
18th Mar 20197:00 amRNSCreo founder in Sunday Times 100 UK entrepreneurs
14th Mar 20195:17 pmRNSHolding(s) in Company
12th Mar 20199:19 amRNSSpeedboat in BSG Endoscopy best video abstract
6th Mar 201912:58 pmRNSExercise of Options
11th Feb 20197:00 amRNSDistribution agreement for France, Germany, Italy
24th Jan 201911:17 amRNSGrowth & Innovation Forum 2019
16th Jan 20197:00 amRNSFirst use of Speedboat in the US
17th Dec 20184:28 pmRNSExercise of Options
3rd Dec 20187:00 amRNSFirst placement and use of Speedboat in Europe
23rd Nov 201810:43 amRNSDirector/PDMR Shareholding
19th Nov 20181:30 pmRNSExercise of Options
22nd Oct 20182:52 pmRNSHolding(s) in Company
19th Oct 20187:00 amRNSUK Endoscopy Training Course
17th Oct 20187:00 amRNSSpain & Benelux Framework Distribution Agreements
12th Oct 20187:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.